• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Critics allege misleading campaigns, poorly-cited data fueled opioid addiction crisis

June 2, 2017 By Sarah Faulkner

PillsThe state of Ohio filed a lawsuit against opioid-makers this week, alleging that the companies produced misleading marketing schemes to convince doctors and patients that opioids were not addictive.

Ohio isn’t alone – Mississippi and West Virginia have filed similar cases against major players in the pharmaceutical industry. Purdue Pharma, Johnson & Johnson (NYSE:JNJ), Endo Pharmaceutical, Teva Pharmaceutical (NYSE:TEVA) and others were named in the Ohio case.

The state hopes to recover money it has spent on opioids and on programs that help people suffering from opioid addiction.

Opioid abuse is rampant in the U.S. – 91 Americans die every day from an opioid overdose, according to the Centers for Disease Control & Prevention. Opioids including fentanyl and hydrocodone kill more than twice as many people as they did a decade ago.

Once used for acute pain, doctors are now prescribing opioids to help their patients manage chronic pain. This often means prescribing opioids for long stretches of time and according to Ohio’s lawsuit, drug-makers spent “millions of dollars on promotional activities and materials that falsely deny or trivialize the risks of opioids while overstating the benefits of using them for chronic pain.”

While states are pointing towards misleading marketing campaigns, other critics have said that poorly-cited data from scientific journals has helped fuel today’s addiction crisis. This week, The New England Journal of Medicine issued a first-of-its-kind editor’s note to a highly-influential 1980 letter about opioid addiction.

The one-paragraph letter reports that “despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.”

The journal added a brief statement to the top of the letter, writing that “for reasons of public health, readers should be aware that this letter has been ‘heavily and uncritically cited’ as evidence that addiction is rare with opioid therapy.”

In reaction to Ohio’s lawsuit, OxyContin-maker Purdue released a statement, saying that it is concerned about the opioid crisis and that it is working to develop abuse-deterrent technology.

Endo Pharmaceuticals has had it’s own problems with abuse-deterent opioids – in March, a FDA panel ruled that the benefits of its opioid painkiller, Opana ER, no longer outweigh its risks. The painkiller has been linked to a 2015 HIV outbreak in Indiana after people addicted to opioids shared needles while injecting Opana.

Filed Under: Featured, Legal News, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Endo Pharmaceuticals, johnsonandjohnson, purduepharma, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS